Related references
Note: Only part of the references are listed.Toward optimized front-line therapeutic strategies in patients with metastatic colorectal cancer-an expert review from the International Congress on Anti-Cancer Treatment (ICACT) 2009
R. Adam et al.
ANNALS OF ONCOLOGY (2010)
Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009
E. Van Cutsem et al.
ANNALS OF ONCOLOGY (2010)
Is response rate increment obtained by molecular targeted agents related to survival benefit in the phase III trials of advanced cancer?
K. Tsujino et al.
ANNALS OF ONCOLOGY (2010)
Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment
E. Van Cutsem et al.
ANNALS OF ONCOLOGY (2010)
Impact of portal vein embolization on long-term survival of patients with primarily unresectable colorectal liver metastases
D. A. Wicherts et al.
BRITISH JOURNAL OF SURGERY (2010)
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial
Gunnar Folprecht et al.
LANCET ONCOLOGY (2010)
A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer
M. Ychou et al.
ANNALS OF ONCOLOGY (2009)
Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study
E. Van Cutsem et al.
ANNALS OF ONCOLOGY (2009)
Long-Term Survival After Liver Resection for Colorectal Liver Metastases in Patients With Hepatic Pedicle Lymph Nodes Involvement in the Era of New Chemotherapy Regimens
Elie Oussoultzoglou et al.
ANNALS OF SURGERY (2009)
Long-Term Outcome of Initially Unresectable Metastatic Colorectal Cancer Patients Treated with 5-Fluorouracil/Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Followed by Radical Surgery of Metastases
Gianluca Masi et al.
ANNALS OF SURGERY (2009)
Timing of Multimodality Therapy for Resectable Synchronous Colorectal Liver Metastases: A Retrospective Multi-Institutional Analysis
Srinevas K. Reddy et al.
ANNALS OF SURGICAL ONCOLOGY (2009)
Response to Neoadjuvant Chemotherapy Does Not Predict Overall Survival for Patients With Synchronous Colorectal Hepatic Metastases
David J. Gallagher et al.
ANNALS OF SURGICAL ONCOLOGY (2009)
The Case for Selective Use of Pre-Operative Chemotherapy for Hepatic Colorectal Metastases: More Is Not Always Better
Giorgos Karakousis et al.
ANNALS OF SURGICAL ONCOLOGY (2009)
Preoperative Liver Hypertrophy Induced by Portal Flow Occlusion Before Major Hepatic Resection for Colorectal Metastases Can Be Impaired by Bevacizumab
Beatrice Aussilhou et al.
ANNALS OF SURGICAL ONCOLOGY (2009)
Bevacizumab-Related Surgical Site Complication Despite Primary Tumor Resection in Colorectal Cancer Patients
Thierry Bege et al.
ANNALS OF SURGICAL ONCOLOGY (2009)
Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study
Jean-Luc Raoul et al.
BMC CANCER (2009)
Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial
A. Okines et al.
BRITISH JOURNAL OF CANCER (2009)
Randomized phase 3 study of panitumumab with FOLFOX4 compared to FOLFOX4 alone as 1st-line treatment (tx) for metastatic colorectal cancer (mCRC): the PRIME trial
J. Douillard et al.
EJC SUPPLEMENTS (2009)
Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases
M. Klinger et al.
EJSO (2009)
Association of Computed Tomography Morphologic Criteria With Pathologic Response and Survival in Patients Treated With Bevacizumab for Colorectal Liver Metastases
Yun Shin Chun et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Patients With Initially Unresectable Colorectal Liver Metastases: Is There a Possibility of Cure?
Rene Adam et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
Carsten Bokemeyer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
Jolien Tol et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Eric Van Cutsem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Long-Term Results of Two-Stage Hepatectomy for Irresectable Colorectal Cancer Liver Metastases
Dennis A. Wicherts et al.
ANNALS OF SURGERY (2008)
Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy
Hiroshi Nakano et al.
ANNALS OF SURGERY (2008)
Chemotherapy with bevacizumab does not affect liver regeneration after portal vein embolization in the treatment of colorectal liver metastases
Daria Zorzi et al.
ANNALS OF SURGICAL ONCOLOGY (2008)
Cancer statistics, 2008
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2008)
Chemotherapy prior to Hepatic Resection for Colorectal Liver Metastases: Helpful until Harmful?
Eddie K. Abdalla et al.
DIGESTIVE SURGERY (2008)
Effect of preoperative chemotherapy on liver resection for colorectal liver metastases
N. N. Mehta et al.
EJSO (2008)
Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: Myth or reality?
Rene Adam et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Effect of molecular therapeutics on liver regeneration in a murine model
George van Buren et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Preoperative Bevacizumab Does Not Significantly Increase Postoperative Complication Rates in Patients Undergoing Hepatic Surgery for Colorectal Cancer Liver Metastases
Susan B. Kesmodel et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Pathologic Response to Preoperative Chemotherapy: A New Outcome End Point After Resection of Hepatic Colorectal Metastases
Dan G. Blazer et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer
Brigit Gruenberger et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer:: A randomized phase III study
Leonard B. Saltz et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first- line treatment of metastatic colorectal cancer: Updated results from the BICC-C study
Charles S. Fuchs et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Spontaneous, delayed colon and rectal anastomotic complications associated with revacizumab therapy
David A. August et al.
JOURNAL OF SURGICAL ONCOLOGY (2008)
Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases
Srinevas K. Reddy et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2008)
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial
Bernard Nordlinger et al.
LANCET (2008)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
Christos S. Karapetis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Expanding criteria for resectability of colorectal liver metastases
Timothy M. Pawlik et al.
ONCOLOGIST (2008)
Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases
Dario Ribero et al.
CANCER (2007)
Progression-free survival is a surrogate for survival in advanced colorectal cancer
Marc Buyse et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer
Josep Tabernero et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Results from the BICC-C study
Charles S. Fuchs et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy
Rene Adam et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Preoperative chemotherapy for colorectal liver metastases: Impact on hepatic histology and postoperative outcome
Timothy M. Pawlik et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2007)
Presurgical chemotherapy in patients being considered for liver resection
Nancy Kemeny
ONCOLOGIST (2007)
Phase I study of AZD0530, an oral potent inhibitor of Src kinase: First demonstration of inhibition of Src activity in human cancers
J. Tabernero et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A phase I trial of RX-0201 (AKT anti-sense) in patients with an advanced cancer
J. Marshall et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Estimates of the cancer incidence and mortality in Europe in 2006
J. Ferlay et al.
ANNALS OF ONCOLOGY (2007)
Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: A matched case-control study
Michael D'Angelica et al.
ANNALS OF SURGICAL ONCOLOGY (2007)
Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group
Bernard Nordlinger et al.
EUROPEAN JOURNAL OF CANCER (2007)
Management and preparedness for infusion and hypersensitivity reactions
Heinz-Josef Lenz
ONCOLOGIST (2007)
Chemotherapy for colorectal cancer prior to liver resection for colorectal cancer hepatic metastases does not adversely affect peri-operative outcomes
Ajay Sahajpal et al.
JOURNAL OF SURGICAL ONCOLOGY (2007)
Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial
Guillaume Portier et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases
Thomas Aloia et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer
Lee M. Ellis
SEMINARS IN ONCOLOGY (2006)
Guidelines for resection of colorectal cancer liver metastases
O. J. Garden et al.
GUT (2006)
Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases
JN Vauthey et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases
M Karoui et al.
ANNALS OF SURGERY (2006)
Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: Individual patient data from 20,898 patients on 18 randomized trials
DJ Sargent et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Hepatic and extrahepatic colorectal metastases: When resectable, their localization does not matter, but their total number has a prognostic effect
D Elias et al.
ANNALS OF SURGICAL ONCOLOGY (2005)
OncoSurge: A strategy for improving resectability with curative intent in metastatic colorectal cancer
GJ Poston et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab
FA Scappaticci et al.
JOURNAL OF SURGICAL ONCOLOGY (2005)
Neoadjuvant treatment of unresectable colorectal liver metastases:: correlation between tumour response and resection rates
G Folprecht et al.
ANNALS OF ONCOLOGY (2005)
Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment
A Grothey et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer:: A randomized GERCOR study
C Tournigand et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
A two-stage hepatectomy procedure combined with portal vein embolization to achieve curative resection for initially unresectable multiple and bilobar colorectal liver metastases
D Jaeck et al.
ANNALS OF SURGERY (2004)
Tumor progression while on chemotherapy - A contraindication to liver resection for multiple colorectal metastases?
R Adam et al.
ANNALS OF SURGERY (2004)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
The effect of vascular endothelial growth factor on the healing of ischaemic skin wounds
F Zhang et al.
BRITISH JOURNAL OF PLASTIC SURGERY (2003)
Liver regeneration is an angiogenesis-associated phenomenon
TA Drixler et al.
ANNALS OF SURGERY (2002)
Share Paper
